Solid Tumors
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- Details
ClinicalTrials.gov ID:
NCT03822117
Diagnosis Type:
NA
USOR Number:
- Address
7777 Forest Lane, Suite D400
Dallas, TX 75230
P: (972) 566-6647